Alliances

For biotech companies, forming partnerships, joint ventures and other sorts of associations provides a crucial source of capital, credibility and settlement of the access to human and technological capabilities. 
Combining the efforts, the biotech and pharmaceutical companies increase their chances of gaining approval from regulatory bodies to introduce new medicines or personalized diagnosis products into the marketplace.

Of the 691 new medicines awarded FDA approval between 1963 and 1999, 38% were developed through a partnership.  The average of biotech partnerships per pharmaceutical company grow rate was 1.4% annually during the period 1988-1990.  That growth rate reached 5.7% for 1997 and 1998, and it continues to rise unabated.

RELEVANT PARTNERSHIPS

ORYZON and CENIT ONCNOSIS project

In 2005 the CENIT projects were launched in Spain with the purpose of supporting joint research actions. CENIT projects are large industrial-research integrated projects, with large scale and far-reaching scientific and technical scope, carried out by consortia (big companies and SMEs) which outsource public and private research groups. These projects have a strong public funding.

ORYZON decided, together with its reference strategic partner, Ferrer Grupo, to resize their prior joint research and to position in the field of the Molecular Diagnosis. ONCNOSIS was one of the projects selected for funding in the first call of the CENIT program in 2006.

ORYZON and the endometrial cancer project: diagnosis/therapy 

In 2006 we started a joint project with the pharmaceutical group Reig-Jofre in which we co-developed products for molecular diagnosis in endometrial cancer through a equal joint venture, GEADIC Biotech AIE. The new society decided afterward to broad the scope of the activities to the development of biological therapies for this type of cancer.

ORYZON bet on Phage-Display technology

Since its inception, ORYZON has made a heavy technological bet which has got stronger with tools like second versions of bioinformatics analysis of ORF and RNAi libraries used to validate targets; and human antibodies libraries. These platforms allow us to discover and carry out therapeutic developments based on ANTIBODIES, as well as imaging-coupled diagnosis using nanoparticles.

ORYZON has license agreements with Haptogen and Dyax allowing us to commercially develop antibodies for therapeutic use.

ORYZON and the prostate cancer project: diagnosis/therapy 

ORYZON and the Dutch company ProteoNic reached an agreement to use their respective technology platforms on a pilot basis for the development of antibodies to fight prostate cancer.